Exercise As Medicine For Heart Failure: A Novel Intervention To Improve Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$665,585.00
Summary
Heart failure (HF) is a common, debilitating and expensive disease; prognosis remains poorer than for the most cancers. 30,000 Australians are diagnosed every year and 300,000 live with the HF, at an annual cost of ~$1Billion. Exercise training is effective therapy in HF, because it reverses many of the problems that contribute to the reduced lifespan and impaired quality of life of patients with HF. We will test an exciting new type of exercise that promising greater benefit, at lower risk.
Targeting A New Regulator Of Cardiac Pathology To Protect The Heart From Cardiac Dysfunction And Arrhythmia
Funder
National Health and Medical Research Council
Funding Amount
$717,857.00
Summary
Heart failure is associated with high mortality, and treatment of this condition represents a major unmet need. We recently reported that specific lipid species are elevated in hearts of mice with heart failure. The goal of this study is to comprehensively examine the therapeutic potential of targeting these lipid species with drugs.
Regulating Gene Expression Changes In Cardiac Hypertrophy
Funder
National Health and Medical Research Council
Funding Amount
$690,754.00
Summary
Following the success in decoding human genome, i.e. DNA sequence, a major task is to understand how the activity of genes with consequent changes in respective proteins. As proteins are an important component for cell structure and function, such changes in quantity and quality of proteins will play a pivotal role to affect disease development and progression.
Benefit Of 2D-strain Surveillance In Improving Cardiovascular Outcomes In Cancer Patients Undergoing Cardiotoxic Chemotherapy
Funder
National Health and Medical Research Council
Funding Amount
$2,391,979.00
Summary
Cancer survivors are susceptible to heart failure (HF) caused by heart muscle damage from chemotherapy. The current testing for this problem is based on a measure that cannot identify minor changes of cardiac function. Cardiac strain is a sensitive new marker of cardiac function which is predictive of overt dysfunction & HF. This study seeks to identify whether strain can be used to assign treatments that lead to improved cardiac function and are eventually associated with a reduction in HF.
The Aboriginal Cardiovascular Omega-3 Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,090,119.00
Summary
CVD is the primary contributor to life expectancy differentials between Indigenous and non-Indigenous Australians. Even when cardioprotective therapies are optimally used, residual risk of adverse events is often observed. Testing of additional therapies that improve survival among Indigenous people with CVD is required. Omega 3 fatty acids can improve multiple atherogenic pathways. This trial will assess the impact of Omega 3 in Aboriginal patients with CVD.
Screening Evaluation Of The Evolution Of New Heart Failure Extension Study
Funder
National Health and Medical Research Council
Funding Amount
$849,992.00
Summary
Heart failure is a major burden on patients with this condition and on the community. The SCReening Evaluation of the Evolution of New Heart Failure (SCREEN-HF) study is evaluating the use of a blood test to identify individuals with undiagnosed heart failure and abnormal heart function, and those at increased risk of these conditions, so that more people can benefit from currently available therapies for the treatment and prevention of heart failure.
Regulation Of Heart Development And Regeneration By DNA Methylation.
Funder
National Health and Medical Research Council
Funding Amount
$552,709.00
Summary
The adult mammalian heart has an extremely limited capacity for regeneration following a heart attack, which is in stark contrast to the robust regenerative capacity of the newborn heart. How and why mammals lose their ability to regenerate heart tissue after birth is not well understood. We propose a new approach to unravel the complex mechanisms that control gene expression during heart development in rodents and humans, which could provide new therapeutic avenues for heart regeneration.
The Dead Heart Project: When Is A 'dead' Heart Truly Dead?
Funder
National Health and Medical Research Council
Funding Amount
$1,672,053.00
Summary
Best practice treatment for end-stage heart failure is heart transplantation, yet donor heart availability is deficient and limited by current practices. Using extensive basic and clinical research approaches, this project aims to increase donor heart quantity and quality by profiling current and novel donor heart sources, and extending donor heart storage time and quality using a novel transport device and therapeutic agents - thus increasing the number of successful transplant recipients.
Genome-wide Analysis Of Gene Regulatory Networks In Heart Development And Congenital Heart Disease
Funder
National Health and Medical Research Council
Funding Amount
$1,263,954.00
Summary
Despite advances in surgical methods and hospital critical care, congenital heart disease (CHD) remains the leading cause of non-infectious death in children in the first year of life. Severe CHD requires multiple surgeries and a lifetime of emotional and financial burden. In this proposal we will use new molecular and genetic approaches to ask how the network of genes that normally participates in heart development is controlled by regulatory factors, and how the network is disturbed in CHD.
Cardiac Resynchronisation Therapy And AV Node Ablation For Atrial Fibrillation In Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$3,274,979.00
Summary
Heart failure (HF) and Atrial Fibrillation (AF) are both significant health issues that often coexist. Cardiac resynchronisation therapy (CRT) is a proven therapy for HF with ventricular dyssynchrony (uncoordinated contraction of the left ventricle). While CRT reduces symptoms and improves survival in normal rhythm, there are mixed reports in patients with AF. This prospective randomised multicentre study, will assess the role of AV node ablation to improve outcomes in CRT in AF.